Monoclonal antibody therapy for lymphoma

Blood Reviews

Volumn 17, Issue 3, 2003, Pages 143-152

  Campbell, Peter ^a   Marcus, Robert ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Immunotherapy; Lymphoma; Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; CANCER ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE;

ANGIONEUROTIC EDEMA; B CELL LYMPHOMA; BACTERIAL PNEUMONIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANDIDIASIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CROSS RESISTANCE; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HERPES SIMPLEX; HUMAN; HYPOTENSION; HYPOTHYROIDISM; LUNG INJURY; LYMPHOCYTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; NEUTROPENIA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; RIGOR; SEPTICEMIA; THROMBOCYTOPENIA; TIME;

EID: 0038375331     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(03)00005-5     Document Type: Review

References (84)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
2. Nadler LM, Stashenko P, Hardy R et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40: 3147-3154.
3. Miller RA, Maloney DG, Warnke R et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306: 517-522.
4. 2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993; 121: 1121-1132.
5. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
6. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29: 2-9.
7. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644-1652.
8. Berinstein NL, Grillo-Lopez AJ, White CA et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.
9. Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135-3143.
10. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
11. Pangalis GA, Dimopoulou MN, Angelopoulou MK et al. Campath-IH (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol 2001; 18: 99-107.
12. Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-IH) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL. Blood 2002; 100: 768-773.
13. Lundin J, Osterborg A, Brittinger G et al. CAMPATH-IH monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-IH Treatment in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1998; 16: 3257-3263.
14. Rai KR, Freter CE, Mercier RJ et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891-3897.
15. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-IH) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.
16. Osterborg A, Dyer MJ, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-IH. Treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567-1574.
17. Byrd JC, Waselenko JK, Maneatis TJ et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999; 17: 791-795.
18. Pruzanski W, Urowitz MB, Grouix B et al. Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-IH in patients with rheumatoid arthritis. J Rheumatol 1995; 22: 1816-1819.
19. Press OW, Rasey J. Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol 2000; 27: 62-73.
20. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002; 20: 3545-3557.
21. Wiseman GA, White CA, Sparks RB et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001; 39: 181-194.
22. Wiseman GA, White CA, Stabin M et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000; 27: 766-777.
23. Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine (131)1 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259-1266.
24. Kaminski MS, Zasadny KR, Francis IR et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974-1981.
25. Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19: 3918-3928.
26. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97; 101-106,
27. Hainsworth JD, Litchy S, Burris 3rd HA et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261-4267.
28. Ghielmini M, Schmitz S-FH, Cogliatti S et al. Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK trial. Blood 2002; 100: 604 (Abstract).
29. Solal-Celigny P, Brice P, Brousse N et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996; 14: 514-519.
30. Flinn IW, Byrd JC, Morrison C et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96: 71-75.
31. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
32. Czuczman MS. Immunochemotherapy in indolent non-Hodgkin's lymphoma. Semin Oncol 2002; 29: 11-17.
33. Zinzani P. A multicenter randomized trial of fludarabine and mitoxantrone (FM) plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma (FL. Blood 2002; 100: 344 (Abstract).
34. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999; 26: 79-87.
35. Piro LD, White CA, Grillo-Lopez AJ et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655-661.
36. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
37. Sacchi S, Tucci A, Merli F et al. Phase II study with fludarabine and cyclophosphamide plus rituximab (FC+R) in relapsed follicular lymphoma patients. Blood 2002; 100 (Abstract 2246).
38. Czuczman MS, Fallon A, Mohr A et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002; 29: 36-40.
39. McLaughlin P, Hagemeister FB, Rodriguez MA et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 2000; 27: 37-41.
40. VanderMolen LA, Steis RG, Duffey PL et al. Low-versus high-dose interferon α-2a in relapsed indolent non-Hodgkin's lymphoma. J Natl Cancer Inst 1990; 82: 235-238.
41. Hagenbeek A, Carde P, Meerwaldt JH et al. Maintenance of remission with human recombinant interferon α-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998; 16: 41-47.
42. Davis TA, Maloney DG, Grillo-Lopez AJ et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α-2a. Clin Cancer Res 2000; 6: 2644-2652.
43. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.
44. Davis T, Kaminski M, Leonard J et al. Results of a randomized trial of Bexxar (tositumomab and I 131 tositumomab) vs unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma. Blood 2001; 98: 843a (Abstract 3503).
45. Vose JM, Wahl RL, Saleh M et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000; 18: 1316-1323.
46. Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336-4342.
47. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 (+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793-3803.
48. Horning S, Lucas J, Younes A et al. Iodine-131 tositumomab for non-Hodgkin's lymphoma patients who progressed after treatment with rituximab: results of a multicenter phase II study. Blood 2000; 96: 843a (Abstract 2184).
49. Witzig W, White C, Flinn I et al. Zevalin radioimmunotherapy of rituximab-refractory follicular non-Hodgkin's lymphoma. Blood 2000; 96: 507a (Abstract 2183).
50. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
51. Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389-397.
52. Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol 2002; 29: 30-35.
53. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-1932.
54. Mey U, Flieger D, Birkmann J et al. Salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma with dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab: preliminary results of a multicenter phase II trial. Blood 2002; 100: Abstr4778.
55. Wilson W, Gutierrez M, O'Connor P et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin Oncol 2002; 29(Suppl. 2): 41-47.
56. Hertzberg M, Crombie C, Benson W et al. Outpatient-based fractionated ICE chemotherapy for both salvage and stem cell mobilisation in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Blood 2002; 100: Abstr4729.
57. Ghielmini M, Schmitz SF, Burki K et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK. Ann Oncol 2000; 11(Suppl. 1): 123-126.
58. Foran JM, Cunningham D, Coiffier B et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 2000; 11(Suppl. 1): 117-121.
59. Foran JM, Rohatiner AZ, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317-324.
60. Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288-1294.
61. Hiddemann W, Unterhalt M, Dreyling M et al. The addition of rituximab (R) to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL): results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG. Blood 2002; 100: Abstr339.
62. Gianni AM, Cortelazzo S, Magni M et al. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transpl 2002; 29(Suppl. 1): S10-3.
63. Mangel J, Buckstein R, Imrie K et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 2002; 29: 56-69.
64. Kennedy B, Rawstron A, Carter C et al. Campath-IH and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99: 2245-2247.
65. Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153-2164.
66. O'Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165-2170.
67. Keating M, O'Brien S, Lerner S et al. Combination chemo-antibody therapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL). Blood 2000; 96: 514a (Abstract 2214).
68. Garcia-Manero G, O'Brien S, Cortes J et al. Combination fludarabine, cyclophosphamide, and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Blood 2000; 96: 757a (Abstract 3275).
69. Byrd J, Peterson B, Park K et al. Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia: Preliminary results from CALGB9712. J Clin Oncol 2001; 20: 280a (Abstract 1116).
70. Multani PS, O'Day S, Nadler LM et al. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 1998; 4: 2599-2604.
71. Grossbard ML, Lambert JM, Goldmacher VS et al. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993; 11: 726-737.
72. Stone MJ, Sausville EA, Fay JW et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996; 88: 1188-1197.
73. Treon SP, Raje N, Anderson KC. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol 2000; 27: 598-613.
74. Grossbard ML, Fidias P, Kinsella J et al. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma. Br J Haematol 1998; 102: 509-515.
75. Maloney DG, Donovan K, Hamblin TJ. Antibody therapy for treatment of multiple myeloma. Semin Hematol 1999; 36: 30-33.
76. Weber D, Gavino M, Huh Y et al. Phenotypic and clinical evidence supports Rituximab for Waldenstrom's macroglobulinemia. Blood 1999; 94: 125a (Abstract).
77. Treon S, Agus D, Link B et al. Rituximab is an active agent in Waldenstrom's macroglobulinemia. J Clin Oncol 2000; 19: 6a (Abstract).
78. Borchmann P, Schnell R, Fuss I et al. Phase I trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 2002; 100: 3101-3107.
79. Schnell R, Staak O, Borchmann P et al. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002; 8: 1779-1786.
80. Pfeifer W, Levi E, Petrogiannis-Haliotis T et al. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-I). Am J Pathol 1999; 155: 1353-1359.
81. Brugger W. Improving outcomes in transplantation. Semin Oncol 2002; 29: 23-26.
82. Liu SY, Eary JF, Petersdorf SH et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16: 3270-3278.
83. Rebello P, Cwynarski K, Varughese M et al. Pharmacokinetics of CAMPATH-IH in BMT patients. Cytotherapy 2001; 3: 261-267.
84. Hochster H, Weller E, Kuzel T et al. Increased mortality associated with higher dose cyclophosphamide plus fludarabine (CF) in advanced stage indolent lymphoma patients treated on EI496, an Eastern Cooperative Oncology Group (ECOG) and CALGB study. J Clin Oncol 2002; 20: Abstr 1125.